IMPACT BIOMEDICAL INC.

Impact BioMedical Inc. has a highly leveraged capital structure with a current ratio of 0.22, indicating that its current liabilities significantly exceed its current assets. The company's liquidity position is further strained by a negative operating cash flow of -$464,000 and a cash and equivalents balance of only $20,000. Despite having no debt, the company's equity base is modest at $11.46 million, and its market cap of $67.6 million suggests a high valuation multiple relative to its revenue of $7 million. The company's profitability metrics are deeply negative, with a return on equity of -19.95% and a return on assets of -13.39%. These figures are far below the industry norms for pharmaceutical companies, which typically exhibit positive returns on equity and assets. The company's operating income of -$2.29 million and net income of -$2.29 million for Q1 2026 underscore its ongoing financial challenges. Impact BioMedical Inc. generates revenue primarily through its biopharmaceutical and wellness offerings, but the company does not disclose specific segment or geographic revenue breakdowns in its filings. The lack of detailed segment reporting makes it difficult to assess the company's exposure to different markets or product lines. However, the company's focus on licensing and co-development partnerships suggests a diversified approach to revenue generation. The company's growth trajectory is uncertain, with no clear indication of revenue growth in the near term. The company's operating income and net income have remained negative, and there is no evidence of a turnaround in the current fiscal year. The company's future performance will depend on its ability to secure new partnerships and advance its pipeline of healthcare and wellness offerings. The company faces several risk factors, including liquidity constraints and the potential for dilution. The risk assessment indicates a high liquidity risk due to the company's negative operating cash flow and low cash reserves. Additionally, the company has a medium dilution risk, as it has issued additional shares in the past and may do so in the future to fund operations. The company's financial statements also mention commitments and contingencies, which could impact its financial stability. Recent filings and financial statements indicate that the company has been working to backfill key financial metrics such as accounts receivable and property and equipment. The company's balance sheet shows a decline in total assets from $17.4 million at the end of 2025 to $17.09 million in Q1 2026, while total liabilities have increased from $1.85 million to $2.38 million. These trends suggest ongoing financial pressures and the need for the company to secure additional funding or generate revenue to sustain operations.